---
title: "Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab. Clinical evidence covers FORTIFI-HN01, BCA101X1101, and FORTIFI-FLEX. 550 evidence topics quoted from 135 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Ficerafusp alfa

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of HPV-negative head and neck squamous cell carcinoma

<a id="topic-1.1.1-1"></a>

##### Summary: epidemiology

The American Cancer Society estimates 60,480 new cases of oral cavity and pharynx cancer in the United States in 2026, and Siegel et al. estimate a further 12,290 new cases of laryngeal cancer. SEER reports 461,008 people living with oral cavity and pharynx cancer and 87,355 living with laryngeal cancer in 2023. These counts cover all cancers of these sites, of any histology and HPV status; no source in the evidence states the U.S. incidence or prevalence of HPV-negative HNSCC or of recurrent or metastatic disease. Most tumors of the oral cavity, larynx, and hypopharynx are HPV-negative. Among U.S. oropharyngeal cancers in 2012 to 2016, an average of 5,500 of 19,000 annual cases (29%) were HPV-negative.

The HPV-negative share of recurrent or metastatic HNSCC differs by source. Bicara states that “Approximately 80% of patients with R/M HNSCC are HPV-negative.” In KEYNOTE-048, 22% of tumors were HPV-positive. Among U.S. real-world first-line pembrolizumab recipients, 258 (39.9%) had HPV-negative tumors, 233 (36.1%) HPV-positive, and 155 (24.0%) equivocal or unknown. Across all HNSCC, the median age at diagnosis is 66 years for HPV-negative disease, 10% of patients have metastatic disease at diagnosis, and approximately 50% of those with locally advanced disease have recurrence or metastasis after initial therapy (Bicara states “up to 30%”). In SEER-Medicare data on older adults with locally advanced HNSCC, 333 of the resected cohort (66%) and 791 of the unresected cohort (65%) had recurrence.

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/); [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html); [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/); [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-1.1.1-2"></a>

##### Summary: survival and mortality

For all oral cavity and pharynx cancer, SEER reports five-year relative survival of 69.9% overall and 36.0% for the 12% of cases diagnosed at a distant stage; the American Cancer Society estimates 13,150 deaths in 2026. For all laryngeal cancer, five-year relative survival is 62.5% overall and 36.0% at a distant stage (15% of cases), with an estimated 3,960 deaths in 2026. In oropharyngeal cancer, HPV-negative disease had shorter survival than HPV-positive disease: median survival of 20 versus 131 months in a U.S. population-based series, and 3-year overall survival of 57.1% versus 82.4% in a second oropharyngeal cancer cohort (Ang et al., 2010). In first-line recurrent or metastatic HNSCC treated with pembrolizumab in U.S. practice, median real-world overall survival was 9 months with HPV-negative versus 20 months with HPV-positive tumors on monotherapy, and 7 versus 15 months on pembrolizumab plus chemotherapy. In the KEYNOTE-048 total population (all HNSCC), 5-year overall survival was 14.4% with pembrolizumab and 16.0% with pembrolizumab-chemotherapy, versus 6.5% and 5.2% with EXTREME. Among older SEER-Medicare adults with locally advanced HNSCC, median overall survival after recurrence was 23.8 months (resected) and 23.7 months (unresected), against 44.4 and 64.5 months without recurrence.

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html); [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html); [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/); [Ang et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2943767/); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-1.1.1-3"></a>

##### Summary: humanistic and economic burden

The burden figures available cover head and neck cancer or HNSCC as a whole; none is specific to HPV-negative disease. In a secondary analysis, 99 of 230 assessable participants (43%) had a severe late toxicity. Swallowing and speech impairments occur in about 50% of HNSCC survivors after radiotherapy, and HNSCC survivors have a suicide rate of 63.4 cases per 100,000 individuals. In a retrospective study using the Vector Oncology Data Warehouse, the mean monthly health care cost was $14,391, with hospitalization accounting for about 57%. In Medicare and commercial claims from 2004 to 2008, 6-month incremental adjusted total costs were $60,414 per patient for metastatic and $21,141 for recurrent head and neck cancer. In SEER-Medicare, recurrence was associated with higher monthly costs of $3,831 (resected) and $4,730 (unresected). Among participants with head and neck cancer in a study of several cancer types, 66.7% noted that recurrence affected employment, and 25.9% of patients and 44.4% of caregivers in a separate head and neck cancer study reported high financial toxicity.

Source: [Machtay et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911537/); [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/); [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/); [Kim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22475042/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/); [Aguiar-Ibáñez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11792841/); [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Ficerafusp alfa Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: phase 1b efficacy by cohort and data cut

All efficacy results for ficerafusp alfa plus pembrolizumab come from BCA101X1101 (NCT04429542), an open-label, nonrandomized, single-arm phase 1/1b trial in which response was investigator-assessed per RECIST v1.1. No randomized result has been reported; the FORTIFI-HN01 interim analysis is expected in mid-2027.

In the first-line 1500 mg weekly expansion cohort reported by Hanna et al. (2026), with a data snapshot of 20 March 2025, 42 participants received at least one dose and 39 were evaluable for efficacy (28 HPV-negative, 11 HPV-positive); median follow-up was 26.3 months. In the HPV-negative subgroup, the confirmed objective response rate (ORR) was 54% (15 of 28; 95% CI, 34 to 73), including six participants (21%) with complete response, and the clinical benefit rate was 86% (24 participants). Median duration of response was 21.7 months (95% CI, 6.0 to not estimable), median time to response 1.4 months, median progression-free survival (PFS) 9.9 months (95% CI, 4.4 to 22.7), and median overall survival (OS) 21.3 months (95% CI, 9.9 to not estimable); an OS assessment in April 2025 gave a 24-month OS rate of 46% (95% CI, 23 to 65). Confirmed ORRs were 54% with a combined positive score (CPS) of 1-19 (n = 13) and 53% with CPS ≥20 (n = 15). In the HPV-positive subgroup, the confirmed ORR was 27% (3 of 11), median PFS 2.0 months, and median OS 16.4 months. An earlier abstract of the same cohort (data cut 16 December 2024) reported an ORR of 64% (18 of 28) in HPV-negative participants and 54% (21 of 39) overall.

At the 31 March 2026 data cut, an integrated analysis of three HPV-negative cohorts reported, for 750 mg weekly (30 evaluable), 1500 mg weekly (28 evaluable), and 2000 mg every 2 weeks with pembrolizumab 400 mg every 6 weeks (27 evaluable), respectively: confirmed ORRs of 57% (95% CI, 37%-74%), 54% (34%-72%), and 48% (29%-68%); complete response rates of 13%, 25%, and 30%; deep response (≥80% tumor shrinkage) in 47% (8 of 17), 80% (12 of 15), and 77% (10 of 13) of responders; and median PFS of 6.9 (4.6-NE), 9.9 (4.4-22.7), and 12.7 (4.9-NE) months. Median follow-up was 20, 36, and 24 months. In the 1500 mg cohort, median OS was 21.3 months (95% CI, 9.9-33.6) and the 3-year OS rate was 31%; OS was “Not mature” in the other two cohorts. Earlier cuts of the other cohorts reported an ORR of 57% (17 of 30) with a complete response rate of 10% (3 of 30) at 750 mg (9 July 2025), and a confirmed ORR of 48% (13 of 27) with a complete response rate of 26% (7 of 27) at 2000 mg every 2 weeks (16 December 2025). In a post hoc pooled analysis at the March 2026 cut, deep response was associated with longer PFS than partial response with <80% shrinkage (covariate-adjusted hazard ratio 0.35; 95% CI, 0.15-0.91).

Hanna et al. compare the HPV-negative ORR of 54% with “the ORR of 19% with pembrolizumab monotherapy in patients with CPS ≥1 in the KEYNOTE-048 phase III trial”, stating the caveats of cross-trial comparison; no head-to-head study has been conducted. In the dose-escalation combination arm (head and neck or anal canal squamous cell carcinoma, any number of prior lines), four of 13 evaluable participants (31%) had a confirmed response.

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Chung et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6017); [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf); [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated); [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf); [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf); [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf); [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/); [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-1.1.2-2"></a>

##### Summary: phase 1b safety

In the 1500 mg weekly cohort (data snapshot 20 March 2025; 42 participants), treatment-related adverse events (TRAEs) of any grade occurred in 40 participants (95%), grade 3 TRAEs in 19 (45%), and a grade 4 TRAE (pericarditis) in one (2%); no fatal TRAEs were reported. Acneiform dermatitis occurred in 32 participants (76%) and reached grade 3 in five (12%); dermatologic TRAEs of any grade occurred in 36 (86%), with grade 3 events in eight (19%). Investigators gave topical steroids and antibiotics, and no participant discontinued treatment because of dermatitis acneiform or rash TRAEs. Anemia TRAEs occurred in 15 participants (36%), grade 3 in six (14%), and bleeding-related TRAEs in 14 (33%), grade 3 in one (2%). TRAEs led to interruption of ficerafusp alfa in 20 participants (48%) and to its discontinuation in five (12%). Grade ≥3 treatment-emergent adverse events occurred in 33 participants (79%), and treatment-emergent adverse events led to death in three (7%). Patient-reported outcomes were not assessed.

At the 31 March 2026 cut of the three HPV-negative cohorts (750 mg weekly, n = 31; 1500 mg weekly, n = 30; 2000 mg every 2 weeks, n = 30), grade 3 TRAEs occurred in 11 (35%), 15 (50%), and 16 (53%) participants; acneiform dermatitis in 27 (87%), 23 (77%), and 24 (80%); and grade 3 anemia in 3 (10%), 7 (23%), and 8 (27%). Ficerafusp alfa-related treatment-emergent adverse events led to discontinuation in 2 (6%), 3 (10%), and 2 (7%) participants. One participant had grade 4 hypokalemia and one grade 4 pericarditis, and no participant had a grade 5 event related to ficerafusp alfa. In the 15-participant dose-escalation combination arm, acneiform dermatitis occurred in 11 (73%), and no grade 4 TRAEs or treatment-related deaths were observed.

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf); [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-1.1.2-3"></a>

##### Summary: FORTIFI-HN01 and FORTIFI-FLEX design and status

FORTIFI-HN01 (NCT06788990) is a multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial with a planned enrollment of about 650 participants at 231 locations. The phase 2 portion randomized participants 1:1:1 to ficerafusp alfa 1500 mg weekly, ficerafusp alfa 750 mg weekly, or placebo, each with pembrolizumab 200 mg every 3 weeks. Bicara announced 1500 mg weekly as the phase 3 dose in January 2026 and completed the transition to phase 3 in February 2026; participants in the 750 mg arm crossed over to 1500 mg. The phase 3 portion randomizes participants 2:1 to ficerafusp alfa 1500 mg weekly or placebo, each with pembrolizumab (up to 35 cycles), stratified by PD-L1 CPS (1-19 vs ≥20) and disease extent. The primary endpoints are ORR per RECIST 1.1 by blinded independent central review (BICR) at an interim analysis and OS at the final analysis. The registry gives a study start of 2025-01-28 and an estimated primary completion of 2028-04. In November 2026 Bicara reported enrollment sufficient for an interim analysis in mid-2027 and stated a potential U.S. launch in 2028.

The registry inclusion criteria are age ≥18 years; recurrent or metastatic squamous cell carcinoma of the oral cavity, hypopharynx, larynx, or oropharynx, “with documented HPV-negative disease if presenting with OPSCC” (nasopharynx and paranasal sinus primaries excluded); PD-L1 CPS ≥1; no prior systemic therapy in the recurrent or metastatic setting, with systemic therapy given as part of multimodal treatment allowed if completed more than 6 months earlier; measurable disease per RECIST 1.1; and ECOG performance status 0 or 1. Exclusions include progression within 6 months of curative-intent systemic therapy, prior anti-TGFβ therapy, prior anti-EGFR antibody (except radiosensitizing and multimodal treatment for locoregionally advanced disease), immune checkpoint inhibitor therapy completed within 6 months, and active major bleeding or a major bleeding episode within 4 weeks. HPV testing applies to oropharyngeal tumors only; Bicara states that testing for HPV status is “typically only being conducted in tumors originating from the oropharynx”.

The sources differ on the biomarker and assessment criteria:

- HPV status: the EU trial record requires HPV-negative documentation “per central testing” for oropharyngeal tumors and names Qiagen Manchester Limited for development of an HPV DNA assay; both trial-in-progress abstracts state that HPV status of oropharyngeal tumors is confirmed by central laboratory testing; the ClinicalTrials.gov record states documented HPV-negative disease without naming a testing site or method.
- PD-L1: the ClinicalTrials.gov record states “PD-L1 CPS ≥1” without an assay; the EU record specifies 22C3 immunohistochemistry, with central testing when local documentation is not available.
- Measurable disease: the EU record and the 2025 trial-in-progress abstract require measurable disease assessed by BICR; the ClinicalTrials.gov record and the 2026 abstract state measurable disease per RECIST 1.1 without naming the assessor.
- Prior anti-EGFR therapy: the ClinicalTrials.gov record and the 2026 poster except radiosensitizing and multimodal treatment; the quoted EU exclusion reads “Prior therapy with an anti-EGFR antibody.”
- Bleeding and life expectancy: the EU record and the 2026 poster also exclude participants with a known bleeding diathesis, and the EU record also excludes participants with “rapidly progressing disease in the treating investigator's opinion.”
- In the phase 1b 1500 mg weekly cohort, PD-L1 CPS was assessed locally with 22C3 “or other validated assay”, and oropharyngeal tumors required a p16 immunohistochemistry or HPV molecular test result; oral cavity, hypopharynx, and larynx tumors were considered HPV-negative.

FORTIFI-FLEX (NCT07807163) is a multicenter, open-label, randomized phase 2 trial. All participants receive ficerafusp alfa 1500 mg weekly with pembrolizumab 200 mg every 3 weeks for a 12-week loading phase; participants without progression are then randomized 2:1 to ficerafusp alfa 2250 mg every 3 weeks or continued 1500 mg weekly, each with pembrolizumab 200 mg every 3 weeks. The primary endpoint is the proportion of maintenance-phase participants who are progression-free by BICR per RECIST 1.1 and alive, at approximately 9 months. Estimated enrollment is 160 in the registry and “(n=150-200)” in the corporate presentation. Bicara announced initiation in August 2026; the registry lists an estimated start of 2026-09, 7 locations, and estimated primary completion of 2028-03. Eligibility follows FORTIFI-HN01, except that the EU record requires oropharyngeal HPV-negative status “as determined by a validated test”, accepts 22C3 PD-L1 CPS ≥1 “determined locally or centrally”, and refers to progression after “curative intent platinum-containing systemic therapy”. Bicara expects results by the time of a potential U.S. approval. No results have been reported.

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00); [Ferrarotto et al. (2025a)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS6113); [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129); [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163); [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Ficerafusp alfa

<a id="topic-1.1.3-1"></a>

##### Summary

Ficerafusp alfa is investigational. No price, wholesale acquisition cost, budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then” and expects an interim analysis of FORTIFI-HN01 in mid-2027 “to support a potential approval and U.S. launch in 2028.” In FORTIFI-HN01, every participant receives pembrolizumab 200 mg every 3 weeks for up to 35 cycles, with ficerafusp alfa or placebo given weekly until disease progression or unacceptable toxicity; the cost of ficerafusp alfa would therefore be added to the cost of pembrolizumab for each treated patient.

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm); [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-1.1.3-2"></a>

##### Summary: eligible population inputs

The American Cancer Society estimates 60,480 new cases of oral cavity and pharynx cancer and 12,290 new cases of laryngeal cancer in the United States in 2026; these counts include all histologies and both HPV-negative and HPV-positive disease. Bicara's Form 10-K states that over 90% of head and neck cancer cases are of squamous cell origin, that an estimated 10% of patients have metastatic disease at diagnosis and “up to 30% of additional patients develop a recurrence or metastases over time after initial treatment for advanced HNSCC”, and that an estimated 80% of recurrent or metastatic HNSCC is HPV-negative. In a U.S. real-world cohort treated in the first-line recurrent or metastatic setting, 60.4% of participants had non-HPV associated disease, and 1410 participants (54.7%) received anti-PD-1 monotherapy, 577 (22.4%) anti-PD-1 plus chemotherapy, and 590 (22.9%) cetuximab plus chemotherapy. The pivotal trial requires PD-L1 CPS ≥1; in the first-line trial described in the pembrolizumab label, 85% of tumors had CPS ≥1. Bicara's presentation estimates “~18K” HPV-negative patients newly diagnosed each year in the United States (“~50K” in the United States, EU5, and Japan), based on “Tessellon patient flow modeling; SEER; country-specific registries; literature review”.

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/); [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-1.1.3-3"></a>

##### Summary: comparator regimen costs and cost of recurrent or metastatic disease

Merck lists the price of pembrolizumab at $12,517.44 for each dose given every 3 weeks and $25,034.88 for each dose given every 6 weeks, current as of September 2026. The pembrolizumab label gives treatment for HNSCC as “Until disease progression, unacceptable toxicity, or up to 24 months”, and median real-world time on first-line pembrolizumab monotherapy was 4.2 months (95% CI, 3.5–4.6). Lilly lists cetuximab at $17,235.60 per month for an average-sized patient. In a retrospective study using the Vector Oncology Data Warehouse, the mean monthly health care cost was $14,391 (95% CI, 12,739-16,044), with hospitalization representing about 57% of the total. Among 716 participants treated before or after the introduction of immuno-oncology agents, per patient per month total costs of care in first-line post-platinum therapy were $11,535 after and $9,054 before (p=.002). In 2004 to 2008 Medicare and commercial claims, 6-month incremental adjusted total costs were $60,414 per patient for metastatic and $21,141 per patient for recurrent head and neck cancer. In SEER-Medicare, recurrence of locally advanced HNSCC was associated with higher monthly health care costs of $3,831 (resected) and $4,730 (unresected). None of these cost studies is restricted to HPV-negative disease.

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Lilly ERBITUX cost information (2026)](https://www.lillypricinginfo.com/erbitux); [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/); [Abraham et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31581922/); [Kim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22475042/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

An estimated 60,480 U.S. cases of oral cavity and pharynx cancer will be diagnosed in 2026; no source counts HPV-negative recurrent or metastatic HNSCC. Bicara states that about 80% of recurrent or metastatic HNSCC is HPV-negative, while 258 of U.S. real-world first-line pembrolizumab recipients (39.9%) had HPV-negative tumors; their median real-world overall survival was 9 months on pembrolizumab monotherapy and 7 months with chemotherapy (20 and 15 months with HPV-positive tumors). In KEYNOTE-048, the response rate with pembrolizumab alone was 19.1% (CPS ≥1), and 71.7% of participants receiving pembrolizumab-chemotherapy had grade ≥3 treatment-related adverse events.

All ficerafusp alfa results come from BCA101X1101, an open-label, single-arm phase 1/1b trial with investigator-assessed response. In HPV-negative participants of the 1500 mg weekly cohort (20 March 2025 snapshot), the confirmed objective response rate was 54% (15 of 28), median progression-free survival 9.9 months, and median overall survival 21.3 months; the 3-year overall survival rate was 31% at the 31 March 2026 cut. Of 42 participants, 19 (45%) had grade 3 treatment-related adverse events and 32 (76%) acneiform dermatitis. HPV-negative cohorts had 27 to 30 evaluable participants, patient-reported outcomes were not assessed, and KEYNOTE-048 comparisons are cross-trial.

FORTIFI-HN01 (NCT06788990), a double-blind, first-line phase 2/3 trial of about 650 participants, randomizes 2:1 in phase 3 to ficerafusp alfa 1500 mg weekly or placebo, each with pembrolizumab; primary endpoints are objective response rate by blinded independent central review (BICR) at an interim analysis and overall survival at the final analysis. It enrolls recurrent or metastatic HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx, “with documented HPV-negative disease if presenting with OPSCC”; HPV testing applies to oropharyngeal tumors alone, and nasopharyngeal and paranasal sinus primaries are excluded. It requires PD-L1 CPS ≥1 and no prior systemic therapy for recurrent or metastatic disease, with multimodal systemic therapy completed more than 6 months earlier. The sources differ: the EU record requires HPV documentation “per central testing” and 22C3 PD-L1 testing, neither specified in the ClinicalTrials.gov record; BICR-assessed measurable disease appears in the EU record and the 2025 abstract alone; and the quoted EU anti-EGFR exclusion has no exception for radiosensitizing treatment.

The FDA granted Breakthrough Therapy Designation for CPS ≥1 disease “excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” Bicara expects interim results in mid-2027 to support accelerated approval, and a potential U.S. launch in 2028. No price, randomized result, cost-effectiveness analysis, or health technology assessment exists; ficerafusp alfa would be added to pembrolizumab ($12,517.44 per 3-week dose).

Items to revisit after the interim analysis:

- BICR-assessed response, its durability, and overall survival against placebo plus pembrolizumab.
- Dermatologic, bleeding, and anemia events under randomized comparison.
- The labeled population, HPV test, and PD-L1 assay.
- The dosing regimen (FORTIFI-FLEX tests every-3-week maintenance) and the price.

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf); [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00); [Ferrarotto et al. (2025a)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS6113); [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129); [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/); [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

## Related pages
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
